Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
4.620
-0.040 (-0.86%)
Jan 8, 2025, 4:00 PM EST - Market closed
Valneva SE Revenue
Valneva SE had revenue of 45.82M EUR in the quarter ending September 30, 2024, with 20.36% growth. This brings the company's revenue in the last twelve months to 158.54M, down -28.98% year-over-year. In the year 2023, Valneva SE had annual revenue of 153.71M, down -57.46%.
Revenue (ttm)
158.54M EUR
Revenue Growth
-28.98%
P/S Ratio
n/a
Revenue / Employee
234,519 EUR
Employees
676
Market Cap
376.51M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | 126.20M | 13.16M | 11.64% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 393.90B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.22B |
VALN News
- 2 days ago - Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference - GlobeNewsWire
- 21 days ago - Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India - GlobeNewsWire
- 5 weeks ago - Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal - GlobeNewsWire
- 5 weeks ago - Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 6 weeks ago - Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA - GlobeNewsWire
- 7 weeks ago - European And US Vaccine Stocks Are Under Pressure - Here's WHy - Benzinga
- 2 months ago - Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 - GlobeNewsWire
- 2 months ago - Valneva SE (VALN) Q3 2024 Earnings Call Transcript - Seeking Alpha